Wire · opportunities
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
Abbott received FDA authorization for the Libre Duo 10 Day system, the first dual glucose-ketone continuous monitoring biowearable, aimed at early detection of rising ketones to prevent diabetic ketoacidosis (DKA) and enhancing diabetes management in the US market.
This Wire brief sits within Fusion42's coverage of Digital Health, and 7 sources have reported it between 25 Aug 2026 and 27 Aug 2026.
◆ ◆ The Wire takeaway
Your diabetes tech must now consider continuous ketone monitoring along with glucose to stay competitive in the US. Abbott’s dual sensor creates a new standard in patient care that your product roadmap cannot ignore.
◆ Coverage
7 sources · first reported 25 Aug 2026 · latest 27 Aug 2026
◆ Related on Wire
◆ Topics